PAVmed Inc. (PAVMW)

0.0290 +0.0149 (+105.67%) At close: 01:36PM EDT

PAVmed Inc.

One Grand Central Place
Suite 4600 60 East 42nd Street
New York, NY 10165
United States
212 949 4319
https://www.pavmed.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 25

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Lishan Aklog M.D.	Chairman & CEO	686.3k	N/A	1966
Mr. Dennis M. McGrath CPA	Pres, CFO & Corp. Sec.	517.7k	N/A	1957
Dr. Brian J. deGuzman M.D.	Chief Medical Officer & Exec. VP of Clinical Affairs	427.2k	N/A	1965
Mr. Adrian K. Miller	VP of Investor Relations	N/A	N/A	N/A
Mr. Shaun M. O'Neil	Chief Commercial Officer	N/A	N/A	N/A
James Mitchell M.D.	VP of Digital Health	N/A	N/A	N/A
Ms. Sunny Webb	VP, Data & Analytics	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Corporate governance

PAVmed Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.